The U.S. Food and Drug Administration has accepted Priovant Therapeutics' New Drug Application for brepocitinib to treat dermatomyositis and granted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE